• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » UPDATE: Industry reacts to proposed changes to 510(K) program

UPDATE: Industry reacts to proposed changes to 510(K) program

August 4, 2010 By MassDevice staff

FDA logo

Industry leaders across the medical device landscape began to weigh in on proposed changes to the 510(K) premarket notification program Wednesday, with most expressing relief over the recommendations proposed by the Centers for Devices and Radiological Health.

“The proposals are more benign than many had feared. No radical change to the current process appears likely. ” Leerink Swann analyst Rick Wise wrote in an email to investors. “The concern here is that an already tougher and more demanding FDA might deploy new rules in a way that could make the approval process overall more transparent but also more burdensome.”

On Tuesday, CDRH officials released several recommendations for changing the 510(K) process, the program by which more than 3,000 medical devices are brought to market.

The recommendations are not official guidance yet as they will be open to public comment for 60-days, according to CDRH head Dr. Jeffrey Shuren, who spoke to members of the media in a midday briefing.

However, he said a majority of the proposed changes could be in place within ” a matter of months” if there is not widespread objections. Some provisions, however, might not go into effect until the second independent review of the 510(K) program being conducted by the Institute of medicine comes out in the summer of 2011.

Shuren said that the point of the changes were not intended to reduce the number of devices that use the 510(K) program, as many industry insiders feared would happen. He said the point was to create “a smarter 510(K) program,” and in fact many of the changes called for in the report were hinted at during a “town hall” style meeting with industry that took place in Massachusetts in June.

Among the proposed changes are:

  • The creation of a new device class called “class IIb” devices, which will require manufacturers to provide some form of clinical evidence to prove effectiveness. Shuren said the evidence required would amount to a full clinical trial, which is currently only required for a PMA submission. Instead companies with devices in this new class group would be required to put the devices in the hands of the end users like physicians and nurses to determine if there are “design failures.” He anticipated that only about 8 to 10 percent of the current devices on the market would fall into the class IIb, but specifically named infusion pumps as one product that would be moved into the new group.

    In March, the FDA convened a panel to review the risks posed by the pumps, after 18 recalls were issued for the devices over a five-year period. The watchdog agency made its first moves toward stricter regulation infusion pumps in April, issuing proposed new guidelines advising manufacturers of the devices that they’ll likely have to run more in-depth clinical trials before the FDA clears new pumps.

    He added that the agency had heard numerous complaints from industry that the agency invesitgators were asking for clinical evidence from companies midway through a 510(K) review, which led to costly delays.

  • The creation of a new Center Science Council to guide the agency in science based decision making, which will be chaired by William Maisel, a cardiologist at Beth Israel Deaconess Medical Center.

    Shuren said this group will serve as a “standing body,” responsible for overseeing science-based decision making across CDRH, provide regular audits decisions made by the agency and assess program performance.

    Maisel also serves as the founder and director of the Medical Device Safety Institute at BIDMC and is well known in FDA circles.

  • The agency will issue clarification on its rescission authority to revoke 510(K) clearances and provide evidence whereby a device shouldn’t be used as a predicate device.

    Shuren said that the internal report revealed that 29 percent of the devices applying for a 510(K) clearance in 2009 cited devices that were no longer on the market. He said the agency must do a better job of making sure companies were using updated comparisons in 510(K) applications.

    In addition, the agency will be more transparent about the criteria it uses to revoke a devices 510(k) clearance. Maggie Dietrich. Special Assistant to the Commissioner said on the call the language in the current statute is not sufficiently clear, but that agency has “implicit authority” to revisit previous decisions and will seek to make it more transparent why a device was taken off the market.

    Shuren said that about 100 decisions on 510(K)’s have been reversed since the 510(K) program began in 1976.

The agency also listed several other recommendations including:

  • Create better/quicker communications with industry through a new “notice to industry” tool to communicate changes in premarket expectations.
  • Improving safety by requiring companies to provide up front to reviewers any scientific information known regarding the safety and effectiveness of the device. This is currently not required in the 510(K) program.
  • Streamlining the premarket pathway for lower-risk novel devices by making major reforms in the implementation of the de novo process.
  • Enhancing the science-based professional development for CDRH staff by providing better training, knowledge sharing and creating a network of external experts to keep staff informed of new developments in technology.
  • Create a searchable online public database that provides more detailed, up-to-date information on the devices currently in the market.

The release of the two reports marks the end of a process started last fall when the agency announced it was conducting an internal review of the 510(K) program to find out whether the process protects patients and promotes innovation and what changes, if any, are needed.

“I think they made a very fair and balanced proposal here and hopefully it will provide the clarity that the industry and the investment community need,” Medical Device Consultants Inc. president William Morton told MassDevice. “Our clients have been frustrated because they know the rules are changing, but they don’t know what the new rules will be. This report helps to clarify the situation and the FDA’s expectations.”

Advanced Medical Technology Association CEO Stephen Ubl called the steps to improve the 510(k) process were “commendable” in a prepared statement.

“At the same time,” he added, “there are in excess of 70 proposed changes that, taken together, could result in a significant disruption to a program that has served patients well for more than 30 years. These range from potential changes in the fundamental basis for product clearance to publicly disclosing design schematics in a database where foreign competitors would have access to them.”

“[C]hanges should be targeted, have a corresponding public health benefit and not undermine a system that has a remarkable safety record,” he said.

To download an mp3 recording of Dr. Shuren disussing the proposed changes to the 510(k) process with members of the media, click here.

Filed Under: Uncategorized Tagged With: 510(k) reforms

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS